Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/99129
Title: LIGAND AND SIRNA MEDIATED NANOMEDICINE FOR ENHANCED CHEMOTHERAPY
Authors: ZHAO JING
Keywords: Biodegradable polymers,Cancer nanotechnology,Drug targeting,Molecular biomaterials,Pharmaceutical nanotechnology,Multidrug resistance
Issue Date: 19-Aug-2013
Source: ZHAO JING (2013-08-19). LIGAND AND SIRNA MEDIATED NANOMEDICINE FOR ENHANCED CHEMOTHERAPY. ScholarBank@NUS Repository.
Abstract: TRADITIONAL CHEMOTHERAPY HAS TWO MAJOR DRAWBACKS: NON-SPECIFICITY AND DRUG RESISTANCE. NANOCARRIER FORMULATION IS TO DATE THE MOST PROMISING FORMULATION STRATEGY WHICH ENABLES SUSTAINED, CONTROLLED, AND TARGETED DELIVERY OF THERAPEUTIC AGENTS. LIGAND CONJUGATION CAN REDUCE NON-SPECIFICITY BY SELECTIVELY INTERACTING WITH THE TUMOR CELLS WHICH HAVE AN OVEREXPRESSION OF THE RECEPTORS. IN THE THESIS, WE DEVELOPED STRATEGIES TO PRECISELY CONTROL AND QUANTIFY THE TARGETING EFFECT OF HERCEPTIN CONJUGATED VITAMIN E TPGS COPOLYMER NANOPARTICLES. SIRNA MEDIATED NANOMEDICINE, THE NANOCARRIER FORMULATION OF ANTICANCER DRUG AND THE SIRNA WHICH SILENCES THE GENE RESPONSIBLE FOR THE DRUG RESISTANCE, CAN BE A STRATEGY TO ALLEVIATE DRUG RESISTANCE. IN THE THESIS, WE DEMONSTRATED ON MULTIPLE CELL LINES THAT THE CO-DELIVERY OF POLO-LIKE KINASE 1 SIRNA (SIPLK1) AND ANTICANCER DRUGS IN HERCEPTIN CONJUGATED VITAMIN E TPGS BASED MICELLES AND NANOGELS SIGNIFICANTLY IMPROVED THE THERAPEUTIC EFFICACY OF THE DRU
URI: http://scholarbank.nus.edu.sg/handle/10635/99129
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ZhaoJ.pdf3.35 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

126
checked on Dec 11, 2017

Download(s)

22
checked on Dec 11, 2017

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.